Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Antibody Drug Conjugates and Recent Applications in Breast Cancer TreatmentПодробнее

IMMU-132 - a novel antibody-drug conjugate for the treatment of lung cancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug ConjugatesПодробнее

Community Context: Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer CareПодробнее

ADC’s - What Everyone with MBC Should Know about Antibody Drug ConjugatesПодробнее

Where are we in sequencing ADCs in HR+ breast cancer?Подробнее

Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhDПодробнее

Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate...Подробнее

Insights into a novel antibody-drug conjugate in myeloma: HDP-101Подробнее

GMF-1A3, a novel ADC targeting cleaved amphiregulin in breast cancerПодробнее

2nd generation ADC technologyПодробнее

Antibody Drug Conjugates for CancerПодробнее

Integrating Antibody-Drug Conjugates into MGMT of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

Antibody-drug Conjugates in the Clinic:Подробнее

The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)Подробнее

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast CancerПодробнее